Boston Scientific Misses Forecasts After Cyberattack Disrupts Global Operations

BENGALURU, India — Boston Scientific Corp. announced Monday that it no longer expects to meet its third-quarter and full-year 2026 sales and adjusted profit forecasts following a significant cybersecurity incident that disrupted operations across its global network. The medical device manufacturer stated the breach has forced a revision of its financial outlook as the company works to restore critical systems.

The disruption began after unauthorized activity was detected on certain information technology systems, triggering a widespread network outage. The incident compromised access to essential operating systems and business applications, halting manufacturing lines and impeding the processing and shipment of customer orders. While the company has not specified the exact nature of the threat actor or the method of entry, the impact has been felt across multiple regions, including its facilities in Bengaluru.

Boston Scientific, a leading maker of cardiovascular and surgical devices, confirmed that the outage is affecting its ability to fulfill demand and maintain standard production schedules. The company's guidance revision signals a potential shortfall in revenue for the remainder of the fiscal year as it navigates the recovery process. Executives indicated that the full financial impact remains under assessment as the extent of the operational delays becomes clearer.

The incident underscores growing vulnerabilities within the medical technology sector, where reliance on interconnected digital infrastructure is critical for both manufacturing and patient care logistics. Boston Scientific has activated its incident response protocols to contain the unauthorized access and restore data integrity. Security teams are working around the clock to rebuild affected systems and ensure that no sensitive patient or proprietary data was exfiltrated during the breach.

Regulatory bodies in the United States and other jurisdictions have been notified of the incident, though no formal investigations have been announced as of Monday morning. The company emphasized its commitment to transparency and is cooperating with relevant authorities to determine the scope of the attack. Shareholders are awaiting further details on how long operations will remain impaired and whether additional financial provisions will be necessary.

As the situation develops, questions remain regarding the timeline for a full return to normalcy. Investors and industry analysts are watching closely to see if the disruption will extend into the fourth quarter or if Boston Scientific can accelerate its recovery efforts. The company has promised to provide updates as more information becomes available, but the path to restoring its original financial targets remains uncertain.